Back to today’s briefing

Story perspectives

NHS Expands Abiraterone Access, Boosts Prostate Cancer Survival

1/17/2026

28 7

Summary

Story summary

The National Health Service (NHS) will provide abiraterone to men in England with high-risk, non-metastatic prostate cancer.
Advocacy by Prostate Cancer UK helped secure the expansion, benefiting about 8,000 men annually.
Clinical trials show abiraterone increases survival, with 86% after six years versus 77% for standard treatment.
Health Secretary Wes Streeting welcomed the decision and urged rapid rollout, which could save about 3,000 lives.

1 of 1

Story summary

The National Health Service (NHS) will provide abiraterone to men in England with high-risk, non-metastatic prostate cancer.
Advocacy by Prostate Cancer UK helped secure the expansion, benefiting about 8,000 men annually.
Clinical trials show abiraterone increases survival, with 86% after six years versus 77% for standard treatment.
Health Secretary Wes Streeting welcomed the decision and urged rapid rollout, which could save about 3,000 lives.